Biora Therapeutics (BIOR)

• Market cap: $8.01M
• 1 day: -14.62%
• 5 days: -36.93%
• 1 month: -57.91%
• 3 months: -74.11%
• 6 months: -75.21%
• Year to date: -86.39%
• 1 year: -86.49%
• 5 years: -99.94%
• 10 years: -99.94%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Biora Therapeutics Inc is a biotechnology company engaged in developing oral biotherapeutics. Its drug-device combinations could enable new treatment approaches in the delivery of therapeutics in two main areas: Targeted delivery of therapeutics to the site of disease in the gastrointestinal ("GI") tract, which is designed to improve outcomes for patients with Inflammatory Bowel Disease (IBD); and Systemic delivery of biotherapeutics, which are designed to replace injection with needle-free, oral delivery technology.

Employees: 58

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

0% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]

0% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 4

0.75% less ownership

Funds ownership: 34.25% [Q2] → 33.5% (-0.75%) [Q3]

24% less capital invested

Capital invested by funds: $8.11M [Q2] → $6.13M (-$1.98M) [Q3]

31% less funds holding

Funds holding: 29 [Q2] → 20 (-9) [Q3]

69% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 13

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $23 1,171% upside
• Avg. target: $23 1,171% upside
• High target: $23 1,171% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Joseph Pantginis 35% 1-year accuracy 117 / 335 met price target

1,171% upside $23

Buy Maintained

18 Nov 2024